Moolec Science (MLEC) director reports long-dated option holdings

Rhea-AI Filing Summary

Moolec Science SA director Leon Bentancor Oscar Alejandro filed an initial Form 3 reporting option-based holdings in the company’s ordinary shares. He holds three direct share option positions, each with an exercise price of 7.1400 per share, covering 934, 933 and 933 ordinary shares with expirations in 2031, 2032 and 2033.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Leon Bentancor Oscar Alejandro

(Last) (First) (Middle)

LEYENDA PATRIA 3148 2

(Street)

MONTEVIDEO 11300

(City) (State) (Zip)

URUGUAY

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
02/06/2026

3. Issuer Name and Ticker or Trading Symbol
Moolec Science SA [ MLEC ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Ordinary shares	02/06/2026	06/30/2031	Share Option	934	$7.14	D
Ordinary shares	06/30/2027	06/30/2032	Share Option	933	$7.14	D
Ordinary shares	06/30/2028	06/30/2033	Share Option	933	$7.14	D

Explanation of Responses:

	/s/ Oscar Leon Bentancor	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Moolec Science (MLEC) Form 3 filing disclose?

The Form 3 discloses director Leon Bentancor Oscar Alejandro’s initial holdings in Moolec Science SA. He reports three direct share option positions over ordinary shares, each exercisable at 7.1400 per share and expiring in 2031, 2032 and 2033, establishing his baseline equity exposure.

How many Moolec Science ordinary shares are covered by the director’s options?

The director holds three option positions covering 934, 933 and 933 Moolec Science ordinary shares. These options provide the right to acquire those shares in the future at a fixed exercise price of 7.1400 per share, subject to their respective expiration dates between 2031 and 2033.

What are the exercise prices and expiration dates of the Moolec Science options?

All reported options have an exercise price of 7.1400 per ordinary share. The options expire on 30 June 2031, 30 June 2032 and 30 June 2033, giving the director long-dated potential to acquire Moolec Science equity if he chooses to exercise before those dates.

Is the Moolec Science Form 3 filing a buy or sell transaction?

The Form 3 is not a buy or sell transaction; it is an initial ownership report. It lists existing option-based positions in Moolec Science ordinary shares, with no open-market purchases or sales and no explicit acquisition or disposition activity reported in the summarized data.

Are the Moolec Science share options held directly or indirectly by the director?

The reported Moolec Science share options are held directly by the director. The filing classifies ownership as direct, with no additional nature-of-ownership description or separate holding entities noted in the summarized data for these option positions over ordinary shares.